Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift - Summary - MDSpire
Advertisement
Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift
To report a case of refractory acrodermatitis continua of Hallopeau (ACH) successfully treated with local injections of an IL-17 inhibitor, highlighting the significance of avoiding immune drift.
Key Findings:
Local injections of Xeligekimab led to significant improvement in skin lesions, with metrics indicating substantial clinical benefit.
No recurrence of eczematous eruptions or systemic adverse reactions were observed.
PPPASI decreased from 14.4 to 1.2, DLQI from 24 to 4, and NAPSI from 160 to 60 over 16 weeks, demonstrating effective treatment.
Interpretation:
Local administration of an IL-17 inhibitor may effectively control ACH while preventing systemic immune imbalance, suggesting a promising avenue for future treatments.
Limitations:
This is a single case report and requires further validation in larger, more diverse studies.
Conclusion:
Local injection of IL-17 inhibitors presents a novel treatment approach for refractory ACH, warranting further research to validate these findings.
